ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 161 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2017. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $5,084,000 | -34.8% | 75,000 | -32.3% | 0.74% | -29.7% |
| Q4 2016 | $7,793,000 | -0.9% | 110,842 | 0.0% | 1.05% | +21.1% |
| Q3 2016 | $7,863,000 | +45.0% | 110,842 | 0.0% | 0.87% | +12.7% |
| Q2 2016 | $5,421,000 | -21.8% | 110,842 | +1.2% | 0.77% | -26.3% |
| Q1 2016 | $6,932,000 | -43.6% | 109,500 | 0.0% | 1.04% | -29.0% |
| Q4 2015 | $12,284,000 | +16.5% | 109,500 | 0.0% | 1.47% | -12.7% |
| Q3 2015 | $10,546,000 | +1.0% | 109,500 | +7.4% | 1.68% | +21.2% |
| Q2 2015 | $10,444,000 | +64.9% | 102,000 | 0.0% | 1.39% | +41.9% |
| Q1 2015 | $6,333,000 | +20.3% | 102,000 | -15.0% | 0.98% | +20.6% |
| Q4 2014 | $5,266,000 | -22.5% | 120,000 | 0.0% | 0.81% | -41.9% |
| Q3 2014 | $6,792,000 | +26.1% | 120,000 | 0.0% | 1.40% | -2.1% |
| Q2 2014 | $5,387,000 | +83.7% | 120,000 | +100.0% | 1.43% | +111.7% |
| Q1 2014 | $2,933,000 | – | 60,000 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |